Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Study of BAR502 in Healthy Subjects
NCT06705998Phase 1Completed
- Sponsor
- BAR Pharmaceuticals s.r.l.
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of BAR502 in Nonalcoholic steatohepatitis (NASH) (3 arms), sponsored by BAR Pharmaceuticals s.r.l. Primary endpoints: Treatment-emergent adverse events and Change in vital signs (BP, HR). Started Dec 2024; status: completed.
02
Drugs
BAR502
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT06705998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06705998.